We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.
Action for Global Health UKLearn moreMore info about Action for Global Health UKAction for Global Health (AfGH) is a network of over 50 organizations working in global health. They connect members with key decision-makers, provide opportunities for joint advocacy and campaigning, and foster a collaborative community to drive progress towards Sustainable Development Goal 3 (Good Health and Well-being).Visit the website
UK Working Group on NCDsLearn moreMore info about UK Working Group on NCDsThe UK Working Group on NCDs is a coalition of over 20 UK-based civil society organizations focused on non-communicable diseases (NCDs) as a critical international development issue. Their
MLTC (Multimorbidity)
statistics on MLTC (Multimorbidity
37.2%of adults worldwide are living with multiple chronic conditions
3/4deathsGLOBALLY DUe to chronic conditions in 2019
* Read statistics sources
https://gco.iarc.fr/
Reducing the impact of multimorbidity
Our research aims to generate strong evidence for policymakers, healthcare providers, and communities to better understand and respond to the burden of multimorbidity.
We are collaborating with global partners, including Imperial College London, to drive innovative solutions that reduce the impact of multiple chronic conditions on both individuals and healthcare systems.
Specifically, the research focuses on:
Identifying common disease clusters and the main risk factors causing them.
Exploring effective ways to prevent multimorbidity.
Developing new, patient-focused methods for better diagnosis, treatment, and management of multiple chronic conditions.
Reducing the overall burden of mul
What are clinical and community trials
What are clinical trials?
Clinical trials are research studies with humans, designed to test new treatments to find better ways to prevent, detect or treat disease1. Clinical trials are also sometimes referred to as interventional trials. The sorts of treatments being investigated include medicines or drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, and other items.2 Clinical trials rely on having members of the general public agree to take part.
What happens in a clinical trial?
In a clinical trial, participants meet with researchers who go through what the clinical trial will involve. All participants must be advised about the objectives of the research, what is expected of them, as well as any risks that may be experienced during and after the trial.
Trials must follow a carefully controlled protocol, which is a plan that describes what researchers will do in the stu
Centre for Operational and Research Excellence
The Centre for Operational and Research Excellence (CORE) is a global group and provides high-quality expertise as well as robust operations, systems and processes to deliver The George Institute’s research strategy.
CORE’s strategy is to:
Achieve and maintain quality and integrity in research
Build core skills and capacity in research operations
Build and maintain robust systems and processes to enable and support research operations
Knowledge management in research operations across The George Institute
CORE’s functional activities include:
Data Management: DM planning, database build and maintenance, quality data management practices, data cleaning, data sharing processes
Project operations: budget development for funding applications, project start-up, implementation and close-out to high quality standards
Quality Assurance: review, and assessment of project quality and risk, provision of guidance for project teams, devel
Innovative clinical trials
Researchers at The George Institute for Global Health, UK, led by Executive Director Professor Otavio Berwanger, are spearheading a programme of work to transform that way we deliver large-scale clinical trials.
This programme is borne out of a recognition of the limitations of the ‘traditional’ clinical trial model – and the health gains (social, environmental and economic) – to be had in investigating pragmatic, innovative and efficient approaches.
In both the so-called ‘traditional’ and innovative trial models, the gold standard of randomisation controls for both known and unknown confounding factors that could influence trials outcomes, and represents the optimal method to work out whether a healthcare intervention reduces the risk of patient-important outcomes and so inform clinical practice.
Where the two models differ is that the traditional approach requires participants be screened and recruited in a trial site by a team of investigators, and so demands both a
Health 10x Accelerator
Since 2019, the Health 10x Accelerator has supported Australia’s brightest health and medtech entrepreneurs in developing affordable and scalable solutions to the world’s most pressing unmet health and medical needs.
Delivered in partnership with UNSW, the 10-week program provides startups with funding, mentorship, and resources to navigate regulatory pathways, refine investment strategies, and scale globally. Key partners, including Australian Medical Angels, Virtus Health, and Luminary Partners - Ignite, offer additional support in coaching, investment, and specialised expertise.
In 2025, Health 10x will partner with the UNSW Tyree Institute of Health Engineering (iHealthE) to further drive innovation. Startups will gain access to state-of-the-art facilities, collaboration spaces, and commercialisation specialists, enhancing their ability to create impactful solutions that transform global health outcomes, particularly in underserved markets.
statistic
Embracing technology
For over a decade, our award-winning digital platform SMARThealth has already been empowering frontline community health workers to identify, refer and manage early signs of cardiovascular disease in local communities in India and Indonesia. Over a decade later, our technology is evolving, now using a bespoke large language model chatbot to remove in-built gender bias in guideline-based advice for pregnant women.
In Australia, we’re using machine learning to be able to predict the risk of cardiovascular disease in women using routine screening mammography, which could potentially lead to a low cost “two for one” screening test that may be more accurate than traditional methods.
SMARThealth ChatGPT : Supporting community health workers to provide guideline-based maternal care in rural IndiaLearn more
Predicting cardiovascular risk using routine mammograms
Learn more
Investing in the future of health innovation
Across Australia, many people struggle to access quality healthcare for mental health support and treatment for chronic conditions. Geographic isolation, limited resources, and systemic inequities are just some of the factors contributing to these gaps. To address these challenges and create lasting change, affordable and scalable solutions are urgently needed.
Soul Patts, one of Australia’s most respected investment companies, is partnering with The George Institute to support cutting-edge tech startups that are driving solutions for unmet medical needs. This partnership goes beyond financial investment, combining long-term funding with strategic guidance to create meaningful and sustainable impact.
By offering pro bono expertise in areas such as strategy, financial management, recruitment, and legal support, Soul Patts is helping startups address skill gaps and accelerate their growth. This dual investment will help these startups scale their operations and deliver sustainable impact
Laying the foundations for innovative healthcare solutions
Professors Robyn Norton AO and Stephen MacMahon AO, co-founders of The George Institute for Global Health, have spent their lives addressing some of the world’s most urgent health challenges. Through decades of groundbreaking research and visionary leadership, they have championed scalable solutions that have inspired a global movement for health equity.
Now, in an extraordinary act of generosity, Robyn and Stephen are giving back to the organisation they built, pledging AUD $1 million to advance two critical areas of women’s health equity.
This gift, combined with a matching contribution from The George Institute, creates a total pool of AUD $2 million. This funding has enabled the establishment of the Founders’ Fund, empowering some of the organisation’s most talented people and partners to unite in advancing this vital mission.
Professors Robyn Norton AO and Stephen MacMahon AO, co-founders of The George Institute
Advancing sex and gender equity in health
To
The Workplace Gender Equality Agency’s Gender Pay Gap Report
The Workplace Gender Equality Agency reports the gender pay gaps of Australian organisations and employers are invited to provide a supporting statement.
We are committed to eliminating our gender pay gap with a structured, accountable program of measures across all our offices and welcome this opportunity to provide an update on our progress in Australia.
Please refer to our 2023 Employer Statement on this page for more information.
Download the 2023 statement
What is gender pay gap?
The gender pay gap is the difference in earnings between men and women in the workplace, expressed as a percentage over men’s earnings. It can be measured based on men and women’s average or median earnings. The gender pay gap is different from equal pay, whereby men and women are paid the same amount for the same, or comparable roles.
Our gender pay gap
The median gender pay gap refers to the difference between the median earnings of men and women*, expressed as a per
Movember to fund big data research on diverse prostate cancer experience
News
Joining Hands for a Healthy Future: Insights for Integrating Community Participation in Intersectoral Collaboration for Planetary Health